Company Overview - Heartflow, Inc. is a leader in AI technology for coronary artery disease (CAD) [1] - The company is advancing coronary care by transforming CAD into a screenable, diagnosable, and manageable condition [3] - Heartflow One is the only complete, non-invasive, precision coronary care platform providing patient insights throughout the guideline-directed CCTA pathway [3] - The AI-driven platform includes Roadmap™ Analysis, FFRCT Analysis, and Plaque Analysis, supported by the ACC/AHA Chest Pain Guideline and backed by over 600 peer-reviewed publications [3] - Heartflow has assisted clinicians in managing over 400,000 patients worldwide [3] Upcoming Events - Members of Heartflow management will participate in a fireside chat at the Morgan Stanley 23 Annual Global Healthcare Conference on September 10, 2025, at 6:15 a.m. PT / 9:15 a.m. ET [1] - A live and archived version of the fireside chat will be available on the Investor Relations section of the Heartflow website [2]

Core Insights - Heartflow, Inc. has successfully closed its upsized initial public offering (IPO) of 19,166,667 shares at a price of $19 per share, raising approximately $364.2 million in gross proceeds [1] Company Overview - Heartflow is a leader in AI technology for coronary artery disease (CAD), aiming to transform CAD into a screenable, diagnosable, and manageable condition [4] - The company offers Heartflow One, a complete, non-invasive, precision coronary care platform that provides patient insights throughout the guideline-directed CCTA pathway [4] - The AI-driven platform includes Roadmap™ Analysis, FFRCT Analysis, and Plaque Analysis, and is supported by the ACC/AHA Chest Pain Guideline, with over 600 peer-reviewed publications backing its efficacy [4] - Heartflow has assisted clinicians in managing over 400,000 patients globally [4] IPO Details - The IPO included 2,500,000 shares issued upon the full exercise of the underwriters' option to purchase additional shares [1] - The shares began trading on the Nasdaq Global Select Market under the ticker symbol "HTFL" on August 8, 2025 [1] - J.P. Morgan, Morgan Stanley, and Piper Sandler served as joint book-running managers for the offering, with Stifel and Canaccord Genuity acting as co-managers [1]

Company Overview - Heartflow, Inc. is a leader in AI technology for coronary artery disease (CAD) and aims to transform CAD into a screenable, diagnosable, and manageable condition [4] - The company offers Heartflow One, a complete, non-invasive, precision coronary care platform that provides patient insights throughout the guideline-directed CCTA pathway [4] - Heartflow's AI-driven platform includes Roadmap™ Analysis, FFRCT Analysis, and Plaque Analysis, supported by the ACC/AHA Chest Pain Guideline and backed by over 600 peer-reviewed publications [4] - The company has assisted clinicians in managing over 400,000 patients globally [4] IPO Details - Heartflow announced the closing of its upsized initial public offering (IPO) of 19,166,667 shares at a public offering price of $19 per share, resulting in total gross proceeds of approximately $364.2 million before deductions [1] - The offering included 2,500,000 shares issued upon the full exercise of the underwriters' option to purchase additional shares [1] - Heartflow's common stock began trading on the Nasdaq Global Select Market under the ticker symbol "HTFL" on August 8, 2025 [1] - J.P. Morgan, Morgan Stanley, and Piper Sandler acted as joint book-running managers for the offering, with Stifel and Canaccord Genuity serving as co-managers [1]

Core Points - Heartflow, Inc. has priced its upsized initial public offering (IPO) of 16,666,667 shares at $19.00 per share, aiming for gross proceeds of approximately $316.7 million before expenses [1] - The company has granted underwriters a 30-day option to purchase an additional 2,500,000 shares at the IPO price [1] - Trading on the Nasdaq Global Select Market is set to begin on August 8, 2025, under the ticker symbol "HTFL," with the offering closing expected on August 11, 2025 [1] Company Overview - Heartflow is focused on transforming coronary artery disease (CAD) into a screenable, diagnosable, and manageable condition through its AI-driven platform, Heartflow One [5] - The platform includes features such as Roadmap™ Analysis, FFRCT Analysis, and Plaque Analysis, and is supported by the ACC/AHA Chest Pain Guideline [5] - Heartflow has assisted clinicians in managing over 400,000 patients globally, backed by more than 600 peer-reviewed publications [5]

Core Insights - UnitedHealthcare has announced comprehensive coverage for Heartflow Plaque Analysis, marking a significant advancement in patient access to AI-driven technology for diagnosing and managing coronary artery disease (CAD) [1][2] - The coverage will be effective from October 1, 2025, specifically for patients with acute or stable chest pain and mild-to-moderate coronary artery narrowing [2] - Heartflow Plaque Analysis is the only FDA-cleared, AI-enabled, noninvasive plaque quantification tool, demonstrating a 95% agreement with the gold standard, IVUS [3] Coverage Details - The updated coverage includes all lines of business for UnitedHealthcare, such as Commercial, Medicare Advantage, and Community plans [1] - This decision aligns with guidelines from radiology benefit manager EviCore, enhancing the standard for cardiovascular care coverage [1][2] Clinical Impact - Management changes informed by Heartflow Plaque Analysis resulted in an average LDL cholesterol decrease of 18.7 mg/dL, which is associated with a 15% reduction in the risk of cardiac events [4] - The technology has been shown to change medical management in over half of patients beyond CCTA alone, improving clinical outcomes [3] Company Vision - Heartflow aims to transform CAD from a leading cause of death into a manageable condition, with CAD responsible for one heart attack every 40 seconds in the U.S. [5] - The company has been adopted by over 1,400 institutions globally, indicating a strong commercial presence and commitment to making advanced solutions widely available [5][6]